Key Takeaways ABT appears more attractive on valuation and recent performance in this MedTech comparison.BSX posted 14% Q4 operational sales growth, with strength in EP, WATCHMAN and oncology.Abbott saw strong CGM sales above $7.5B in 2025 and expanded via the Exact Sciences deal.Among large-cap U.S. MedTech companies, Boston Scientific (BSX) and Abbott (ABT) continue to attract significant investor focus. Abbott’s business model is diversified, having leading businesses and products in diagnostics, medical ...

New York, New York--(Newsfile Corp. - February 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws.On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, appr ...

Sometimes the best new ideas are simply old winners ready for another run. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificat ...

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Core Viewpoint - Belo Sun Mining Corp. has successfully reinstated its Installation License for the Volta Grande Gold Project in Brazil, allowing the company to resume construction activities after a suspension since 2017 [1][3][6]. Background - The Federal Court of Altamira had previously upheld the suspension of the Installation License, prompting the company to take legal action to challenge this decision [2]. Court of Appeal Decision - On February 13, 2026, the Federal Regional Court granted interim relief, reinstating the Installation License and permitting Belo Sun to continue installation activities for the Project [3]. Compliance and Consultation - The Court determined that the company had met all conditions set by TRF-1, including the preparation of the Indigenous Component Study based on primary data and conducting consultations with local Indigenous communities in accordance with established protocols [4]. - The Court also ruled that FUNAI's reversal of its earlier position regarding the sufficiency of the ECI was not supported by formal administrative procedures, requiring any new requirements to follow proper technical justification [5]. Construction Activities - With the ruling, the Installation License is now fully effective, allowing the company to proceed with construction and installation activities for the Project [6]. Next Steps - The respondents to the appeal have the opportunity to file a response, and the appeal will be reviewed by the 6th Panel of TRF-1, with further updates to be provided by the company [7]. Company Leadership Comments - The Chairman and CEO of Belo Sun expressed gratitude for the support received from local communities and authorities, highlighting the significance of this milestone for the company and its stakeholders [8][9]. Project Development Commitment - The company aims to develop the project in line with best international mining practices, focusing on environmental protection and social standards to contribute to the region's economic development [10].

Core Insights - Maverick Capital Ltd. established long positions in Google C, Applied Materials, Boston Scientific, Visa, and Camden Property during the fourth quarter [1] - The firm increased its holdings in TSMC, NVIDIA, GFL Environment, and Carvana [1] - Maverick Capital completely exited positions in Kenvue, US Bancorp, AMD, Danaher, and Insmed [1] - The company reduced its stakes in Nubank, Disney, Merit Medical, Acadia Health, and Sherwin-Williams [1] - The firm maintains significant positions in NVIDIA, Microsoft, Amazon, TSMC, and Google C [1]

Core Insights - Boston Scientific (BSX) reported strong fourth-quarter results for 2025, exceeding both revenue and earnings guidance, with over $20 billion in sales and 12.7% organic revenue growth [1][8] - The company faced challenges in Urology due to supply-chain issues and competitive pressures in Electrophysiology, leading to a 17.6% drop in stock price post-earnings announcement [2][3] Financial Performance - Boston Scientific achieved mid-teens growth for the second consecutive year, attributed to innovation and execution across business units [1] - The company expects organic growth of 10%-11% for 2026, despite near-term challenges [9][12] Segment Highlights - WATCHMAN business grew 29% year-over-year in Q4, supported by strong adoption in U.S. procedures and a strategic partnership with Siemens Healthineers [4] - Neuromodulation sales increased by 10% in Q4, with a full-year organic growth of 8%, bolstered by new product offerings and expanded reimbursement coverage [5] - APAC region sales surged 15% operationally in Q4, driven by strong performances in Japan and China [6] Market Position and Challenges - Boston Scientific holds approximately 65% market share in the PFA market, with expectations to exceed the 15% market growth rate despite competitive pressures [10] - The company announced acquisitions of Valencia Technologies and Penumbra to enhance its urology and cardiovascular capabilities [11] Profitability Outlook - Adjusted gross margin is expected to remain stable, with operating margin projected to expand by 50-75 basis points, and adjusted EPS anticipated to grow by 12%-14% [12] - First-quarter 2026 revenue growth is guided at 8.5%-10%, facing challenges from product discontinuations [13] Valuation Metrics - Boston Scientific trades at a forward Price/Sales (P/S) ratio of 4.87, which is below its historical median but above the industry average of 2.67 [17] Conclusion - Despite recent stock performance challenges, Boston Scientific's strong fundamentals and growth potential in key segments suggest a prudent hold for investors, with an attractive valuation relative to competitors [18]

Summary of China Medtech Q425 Conference Call Industry Overview - **Industry**: Medical Technology (Medtech) in China - **Context**: The conference call discusses the performance of various global medtech companies in China during Q425, highlighting ongoing challenges and opportunities in the market for 2026. Key Points 1. Overall Market Sentiment - Many large-cap global medtech companies reported a year-over-year (YoY) decline in China revenue for Q425, particularly in the diagnostics (Dx) sector. Companies expect policy headwinds to persist into 2026, albeit at a reduced impact level [2][4] 2. Equipment Sector Performance - **GE Healthcare**: Reported an 11% YoY revenue decline in China for Q425, with flat revenue quarter-over-quarter (QoQ). The company noted improved VBP (Volume-Based Procurement) win rates and a stronger imaging funnel but still anticipates a decline in 2026 revenue guidance for the China business [3][4] - **Siemens Healthineers**: Experienced a 5% YoY decline in China revenue for Q425, with imaging and precision therapy segments remaining flat. The Dx revenue sharply fell due to VBP and reimbursement cuts, with expectations of a flat volume development for the non-Dx business in FY26 [3][4] - **Intuitive Surgical**: Reported a drop in placements in China from 20 to 17 in Q425, citing intensified competition from local suppliers and lower pricing in provincial tenders [3] 3. Diagnostics Sector Challenges - **Roche**: The China Dx segment faced a 12% YoY revenue decline in Q425, with core lab oncology reagents down approximately 50% in 2025. The company expects continued but diminishing headwinds in 2026 [4] - **Abbott**: Estimated a US$400 million headwind from VBPs, indicating that most of its Dx sales in China have already been affected by these reforms [4] - **Danaher**: Reported a low single-digit decline in core revenue in China for Q425, with Dx segment under pressure from policy headwinds. The company anticipates a moderation of VBP impacts in 2026 [4] 4. Consumables Sector Growth - **Boston Scientific**: Achieved double-digit revenue growth in China for Q425, driven by electrophysiology (EP) and interventional cardiology therapies. The company expects this momentum to continue into 2026, supported by recent NMPA approvals [5] - **Johnson & Johnson**: Continues to face negative impacts from VBPs across its surgery and orthopaedics portfolio, with expectations of additional rounds of VBPs in 2026 [5] Additional Insights - The medtech industry in China faces several risks, including larger-than-expected price reductions from VBP programs, weaker demand from equipment renewal programs, and geopolitical issues affecting supply chains [8] - The overall sentiment indicates a cautious outlook for 2026, with companies adapting to ongoing policy changes and competitive pressures in the Chinese market [2][4][5]

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, which was approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for the fourth quarter, but management indicated confidence in only about 15% growth going forward, creating a notable gap between market expectations and internal outlook [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential alternative to traditional thermal ablation procedures [3]. - Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has made significant investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - Boston Scientific emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4].